{"schema_version":"secwatch.filing_event.v1","accession":"0001388658-23-000102","form_type":"8-K","ticker":"IRTC","cik":"0001388658","company_name":"iRhythm Holdings, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.761741+00:00","generated_at":"2026-06-12T07:38:38.956709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iRhythm Q2 revenue $124.1M (+21.6% YoY); narrows net loss; guides FY rev $485-490M","bullets":["Revenue $124.1M, up 21.6% YoY; gross margin 69.5%, up 70 bps from 68.8%.","Net loss $18.5M ($0.61/share) vs $23.9M ($0.80) YoY; adjusted net loss $13.1M ($0.43).","Cash, equivalents, marketable securities $164.7M at June 30, 2023.","FY2023 guidance: revenue $485-490M (18-19% growth); gross margin 69-70%; adj. EBITDA ~0-0.5%.","Zio XT new account openings; Japan MHLW high medical needs designation; Shonin application filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001388658-23-000102","json":"https://secwatch.observer/filing/0001388658-23-000102.json","markdown":"https://secwatch.observer/filing/0001388658-23-000102.md","text":"https://secwatch.observer/filing/0001388658-23-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000102/0001388658-23-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000102/irtc-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:38:38.956709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d44424f6b4b2083909188d05a060b2c8d4cc449","claim":"iRhythm Holdings, Inc. reported second quarter ended June 30, 2023 results: revenue $124.1 million, net income $18.5 million, EPS $0.61 per share. Guidance reaffirmed.","evidence_excerpt":"Revenue for the second quarter of 2023 was $124.1 million, up 21.6% from $102.1 million during the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388658/000138865823000102/0001388658-23-000102-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$124.1 million"},{"label":"Net income","value":"$18.5 million"},{"label":"EPS","value":"$0.61 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}